The anti-oestrogen tamoxifen produces haemodilution in normal postmenopausal women.
OBJECTIVE
To report the effects of the anti-oestrogen tamoxifen on biochemical and haematological parameters.


METHODS
Randomized, double-blind comparison of tamoxifen 20 mg per day and placebo, over two years.


METHODS
A university hospital.


METHODS
Forty-six healthy late-postmenopausal women (mean, SD time since menopause; 11, seven years).


METHODS
Blood specimens were drawn in the fasting state at baseline, six months and two years for measurement of haemoglobin, haematocrit, erythrocyte mean cell volume, mean erythrocyte haemoglobin, leucocyte count, platelet count, urea, electrolytes, creatinine and albumin.


RESULTS
There was a significant decline in the haemoglobin concentration in the tamoxifen group (-4.4, 1.2 g/L; mean, SE) and its levels were lower in this group than in those receiving placebo (P = 0.004). Similarly, haematocrit, erythrocyte count and total leucocyte count were lower in those on placebo (P = 0.002, P = 0.01 and P = 0.01, respectively) and platelet count showed a similar trend (P = 0.08). In the tamoxifen group, the level of serum albumin fell significantly (-2.2, 0.4 g/L) and was lower throughout the study than that in the placebo group (P = 0.006). That of serum urea tended to fall (-0.4, 0.2 mmol L) but the between-groups comparison was not significant (P = 0.18).


CONCLUSIONS
These data suggest that tamoxifen exerts a haemodilutory effect in normal postmenopausal women. Since a similar effect has been reported in response to postmenopausal oestrogen therapy, it is likely that the observed changes represent another oestrogenic effect of tamoxifen in postmenopausal women. Haemodilution may contribute to the reduced incidence of cardiovascular disease reported in tamoxifen-treated women, and, therefore, its assessment in the new oestrogen agonists/antagonists being developed for cardiovascular disease prevention may be important.
Grey
A B
AB
Department of Medicine, University of Auckland, New Zealand.
Evans
M C
MC
Kyle
C
C
Reid
I R
IR
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001772:Blood Cell Count / Q000187:drug effects*; D001809:Blood Viscosity / Q000187:drug effects*; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D017698:Postmenopause; D012016:Reference Values; D013629:Tamoxifen / Q000494:pharmacology*; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D006454:Hemoglobins; D013629:Tamoxifen